Skip to main content
SpringerLink
Log in

Long- and short-term side effects and safety of calcitonin in man: A prospective study

  • Clinical Investigations
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Summary

Forty-three patients were treated for a total duration of 301 patient-years with calcitonin (CT) (range 3–16 years, median duration 6 years 6 months). Eighty-four percent of patients were suffering from complications associated with Paget's disease and the remainder from osteoporosis. In the majority of patients, CT was administered by the subcutaneous route and one patient was psychologically dependent on calcitonin injections. There were no long-term side effects associated with CT therapy. In a separate group of 105 patients consisting of 83 patients on human CT and 22 patients on salmon CT, injections showed short-term side effects in 77% and 64% of these patients, respectively (NS). Side effects associated with nasally administered salmon CT in 25 patients were mild and of low incidence (32%). Long-term administration of calcitonin in humans is safe and devoid of any serious or long-term side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Reynolds JJ, Dingle JT (1970) A sensitive in vitro method for studying the induction and inhibition of bone resorption. Calcif Tissue Res 4:339–349

    Google Scholar 

  2. Foster GV, Joplin GF, MacIntyre I, Melvin KEW, Slack E (1969) Effect of thyrocalcitonin in man. Lancet i:107–109

    Google Scholar 

  3. Woodhouse NJY, Bordier P, Fisher M, Joplin GF, Reiner M, Kalu DN, Foster GV, MacIntyre I (1971) Human calcitonin in the treatment of Paget's bone disease. Lancet i:1139–1143

    Google Scholar 

  4. De Rose J, Singer FR, Avramides A, Flores A, Dziadiw R, Baker RK, Wallach S (1974) Response of Paget's disease to porcine and salmon calcitonins. Effects of long-term treatment. Am J Med 56:856–866

    Google Scholar 

  5. Evans IMA (1979) Human calcitonin in the treatment of Paget's disease: long-term trials. In: MacIntyre I (ed) Human calcitonin and Paget's disease. Hans Huber, Bern, pp 111–121

    Google Scholar 

  6. Bijvoet OLM, Sluys Veer JVD, Jansen AP (1968) Effects of calcitonin on patients with Paget's disease, thyrotoxicosis, or hypercalcaemia. Lancet i:876–881

    Google Scholar 

  7. Wimalawansa SJ (1989) Calcitonin: molecular biology, physiology, pathophysiology and its therapeutic uses. In: Pecile A, Bernard B (eds) Advances in bone regulatory factors: morphology, biochemistry, physiology and pharmacology. Plenum Press, England pp 121–160

    Google Scholar 

  8. Bijvoet OLM, Sluys Veer JVD, Jansen AP (1968) Effects of calcitonin on patients with Paget's disease, thyrotoxicosis, or hypercalcaemia. Lancet i:876–881

    Google Scholar 

  9. Brown P, Thin CG, Malone DNS, Roscoe P, Strong JA (1970) Metabolic studies with porcine calcitonin in osteoporosis. Scott Med J 15:207–212

    Google Scholar 

  10. Cohn SH, Dombrowski CS, Hauser W, Klopper J, Atkins HL (1971) Effects of porcine calcitonin on calcium metabolism in osteoporosis. J Clin Endocrinol 33:719–728

    Google Scholar 

  11. Milhaud G, Talbot JN, Coutris G (1975) Calcitonin treatment of post-menopausal osteoporosis. Evaluation of efficacy by principal components analysis. Biomedicine 23:223–232

    Google Scholar 

  12. Wallach S, Cohn SH, Atkins HL, Ellis KJ, Kohlberger R, Aloia JF, Zanzi I (1977) Effect of salmon calcitonin on skeletal mass in osteoporosis. Curr Ther Res Clin Exp 22:556–572

    Google Scholar 

  13. Rasmussen H, Bordier P, Marie P, Auquier L, Eisinger JB, Kuntz D, Caulin F, Argemi B, Gueris J, Julien A (1980) Effect of combined therapy with phosphate and calcitonin on bone volume in osteoporosis. Metab Bone Dis Rel Res 2:107–111

    Google Scholar 

  14. Gruber HE, Ivey JL, Baylink DJ, Matthews M, Nelp WB, Sisom K, Chesnut CH III (1984) Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 33:295–303

    Google Scholar 

  15. Mazzuouli GF, Passeri M, Gennari C, Minisola S, Antonelli R, Valtorta C, Palummeri E, Cervellin GE, Gonnelli S, Francini G (1986) Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 38:3–8

    Google Scholar 

  16. Overgaard K, Riis BJ, Christiansen C, Podenphant J, Johansen JS (1989) Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol 30:435–442

    Google Scholar 

  17. Reginster JY, Denis D, Albert A, Deroisy R, Lecart MP, Fontaine MA, Lambelin P, Franchimont P (1987) 1-year controlled randomized trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet ii:1481–1483

    Google Scholar 

  18. Behn AR, West TET (1977) Emergency treatment with calcitonin of hypercalcaemia associated with myeloma. Br Med J 1: 775–776

    Google Scholar 

  19. Wyn AU (1975) Calcitonin treatment of hypercalcaemia due to parathyroid carcinoma. Arch Intern Med 134:1594–1597

    Google Scholar 

  20. Torring O, Bucht E, Sjostedt U, Sjoberg HE (1991) Salmon calcitonin treatment by nasal spray in primary hyperparathyroidism. Bone 12:311–316

    Google Scholar 

  21. Carey DE, Raisz LG (1975) Calcitonin therapy in prolonged immobilisation hypercalcaemia. Arch Phys Med Rehab 66:640–644

    Google Scholar 

  22. Silva OL, Becker KK (1973) Salmon calcitonin in the treatment of hypercalcaemia. Arch Intern Med 132:336–339

    Google Scholar 

  23. Fleish H (1988) Bisphosphonates: a new class of drugs in bone disease and calcium metabolism. In: Barker PF (ed) Handbook of experimental pharmacology. Springer, Berlin/Heidelberg, vol 83, pp 441

    Google Scholar 

  24. Kanis JA, Percival RC, Yates AJP, Urwin GH, Hamdy NAT (1986) Effects of diphosphonates in hypercalcaemia due to neoplasia. Lancet i:615–616

    Google Scholar 

  25. Morton AR, Cantrill JA, Pillai GV, McMahon A, Anderson DC, Howell A (1988) Sclerosis of lytic bone metastasis after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. Br Med J 197:772–773

    Google Scholar 

  26. Ralston SH, Gallagher SJ, Patel U, Dryburgh FJ, Fraser WD, Boyle IT (1989) Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet ii:1180–1183

    Google Scholar 

  27. Elooma I, Blomqvist C, Grohn P, Porkka L, Kairento AL, Selander K, Lamberg-Allardt C, Holmstrom T (1983) Long-term controlled trial with diphosphonate in patients with osteolytic bone metastasis. Lancet i:146–149

    Google Scholar 

  28. Carstens JH, Feinblatt JD (1991) Future horizons for calcitonin: a US perspective. Calcif Tissue Int 49(suppl 2):S2-S6

    Google Scholar 

  29. Lyritis GP, Tsakalakos N, Magiasis B, Karachalios T, Yiatzides A, Tsekoura M (1991) Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind, placebo-controlled clinical study. Calcif Tissue Int 49:369–372

    Google Scholar 

  30. Gennari C, Agnusdei D, Camporeale A (1991) Use of calcitonin in the treatment of bone pain associated with osteoporosis. Calcif Tissue Int 49(suppl 2):S9-S13

    Google Scholar 

  31. Allen E (1983) Calcitonin in the treatment of intractable pain from advanced malignancy. Pharmatherapeutica 3:482–486

    Google Scholar 

  32. Fabbri A, Santoro G, Moretti C, Cappa M, Fraioli F, Di Julio CG, Galluzzi T, Lamanna V (1981) The analgesic effect of calcitonin in humans: studies on the role of opioid peptides. Int J Clin Pharmacol Ther Toxicol 19:509–511

    Google Scholar 

  33. Singer FR, Alfred JP, Neer RM, Krane SM, Potts JT Jr, Block KJ (1972) An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest 51:2331–2336

    Google Scholar 

  34. Dube WJ, Goldsmith RS, Arnaud SB, Arnaud CD (1973) Development of antibodies to porcine calcitonin during treatment of Paget's disease of bone. Mayo Clin Proc 48:43–48

    Google Scholar 

  35. Ziegler R, Holz G, Raue H, Minne H, Delling G (1976) Therapeutic studies with human calcitonin. In: MacIntyre I (ed) Human calcitonin and Paget's disease. Proc Intl Workshop, London, Huber, Vienna, p 167

  36. Cantalamessa L, Catania A, Roschini E, Peracchi M (1978) Inhibitory effects of CT on growth hormone and insulin secretion in man. Metabolism, 27:987–992

    Google Scholar 

  37. Mitsuma T, Nogimori T, Chaya M (1978) Peripheral administration of eel calcitonin inhibits thyrotropin secretion in rats. Eur J Pharmacol 102:123–126

    Google Scholar 

  38. Judd AM, Kubota T, Kuan SI, Jarvis WD, Spangelo BL, Macleod M (1990) Calcitonin decreases thyrotropin-releasing hormone-stimulated prolactin release through a mechanism that involved inhibition of inositol phosphate production. J Bone Min Res 127:191–199

    Google Scholar 

  39. Wimalawansa SJ, MacIntyre I (1991) Calcitonin. In: Dollery CT (ed). Therapeutic drugs: a clinical pharmacopia. Churchill Livingstone, UK, pp C18-C22

    Google Scholar 

  40. Obie JF, Cooper CW (1979) Loss of calcaemic effects of calcitonin and parathyroid hormone infused continuously into rats using the Alzet osmotic minipump. J Pharmacol Exp Ther 209: 422–428

    Google Scholar 

  41. Haddad JG Jr, Calwell JG (1972) Calcitonin resistance: clinical and immunologic studies in subjects with Paget's disease of bone treated with porcine and salmon calcitonins. J Clin Invest 51:3133–3136

    Google Scholar 

  42. Singer FR, Fredericks RS, Minkin C (1980) Salmon calcitonin therapy for Paget's disease of bone: the problem of acquired clinical resistance. Arthitis Rheum 23:1148–1154

    Google Scholar 

  43. Tashjian AH Jr, Wright DR, Ivey JL, Pont A (1978) Calcitonin binding sites in bone: relationships to biological response and escape. Recent Prog Horm Res 34:285–334

    Google Scholar 

  44. Zanelli JM, Salmon DM, Azria M, Zanelli GD (1984) A rat model for clinical resistance to chronic treatment with salmon calcitonin: application of quantitative cytochemistry. In: Pecile A (ed) Calcitonin: chemistry, physiology, pharmacology and clinical aspects. Excerpta Medica, Amsterdam, pp 223–230

    Google Scholar 

  45. Register JY, Gennari C, Mautalen C, Deroisy R, Denis D, Lecart MP, Vandalem JA, Collette J, Franchimont P (1990) Influence of specific anti-salmon calcitonin antibodies on biological effectiveness of nasal salmon calcitonin in Paget's disease of bone. Scand J Rheumatol 19:83–86

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biochemical Endocrinology Unit, Department of Medicine (Endocrinology) and Chemical Pathology, Royal Postgraduate Medical School, Du Cane Road, W12 ONN, London, UK

    Sunil J. Wimalawansa

Authors
  1. Sunil J. Wimalawansa
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wimalawansa, S.J. Long- and short-term side effects and safety of calcitonin in man: A prospective study. Calcif Tissue Int 52, 90–93 (1993). https://doi.org/10.1007/BF00308314

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00308314

Key words

Search

Navigation